Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.67 |
| ▸ | PPARG | P37231 | 16/20 | 0.64 |
| ▸ | PPARA | Q07869 | 12/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031089 | 0.88 | KDM4E (0.65) | KDM4EFFAR1PPARGPPARAHPGD | |
| SCHEMBL9128417 | 0.88 | FFAR1 (0.67) | KDM4EFFAR1PPARGPPARAHPGD | |
| SCHEMBL5856050 | 0.86 | KDM4E (0.62) | KDM4EFFAR1PPARGPPARAHPGD | |
| SCHEMBL27527229 | 0.85 | KDM4E (0.61) | KDM4EFFAR1PPARGPPARAHPGD | |
| SCHEMBL28297237 | 0.85 | FFAR1 (0.61) | KDM4EFFAR1PPARGPPARAPPARD | |
| SCHEMBL13721668 | 0.85 | KDM4E (0.60) | KDM4EFFAR1PPARGPPARAHPGD | |
| SCHEMBL893027 | 0.84 | KDM4E (1.00) | KDM4EFFAR1PPARGPPARAHPGD | |
| SCHEMBL7897351 | 0.84 | FFAR1 (0.83) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL14373654 | 0.84 | KDM4E (0.59) | KDM4EFFAR1PPARGPPARAHPGD | |
| SCHEMBL979145 | 0.83 | KDM4E (0.65) | KDM4EFFAR1PPARGPPARAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357115-B1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-06-17 | — | — | EP | disclosed |
| CN-100467456-C | Alpha-piperazine substituted phenyl-propionic acid derivatives as hPPAR alpha and hPPAR gamma agonist | BEIJING MOLYKOTE TECHNOLOGY CO (CN) | 2009-03-11 | — | — | CN | disclosed |
| CN-100436430-C | Alkanoyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist | INST PHARM & TOXICOLOGY AMMS (CN) | 2008-11-26 | — | — | CN | disclosed |
| US-7371777-B2 | Cyclic compound and PPAR agonist | EISAI CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7238716-B2 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1313716-B1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1313716-B1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-6696474-B2 | SUCH AS 8-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-2-PYRROL-1-YL-OCT-4-YNOIC ACID; NONINSULIN DEPENDENT DIABETES MELLITUS | WARNER LAMBERT CO. LLC. | 2004-02-24 | — | — | US | disclosed |
| WO-2004011446-A1 | INDANE, DIHYDROBENZOFURAN, AND TETRAHYDRONAPHTHALENE CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| CN-1471517-A | OXAZOLYL-arylpropionic acid derivatives and their sue as PPAR agonists | — | 2004-01-28 | — | — | CN | disclosed |
| US-20030220381-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY, LLC | 2003-11-27 | — | — | US | disclosed |
| EP-1357115-A1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003082276-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1313716-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016331-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| US-5330998-A | Anticholesterol agents | PFIZER INC. (US) | 1994-07-19 | — | — | US | disclosed |
| WO-1989008652-A1 | THIAZOLIDINEDIONE DERIVATIVES AS HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1989-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220381-A1 | ANTIDIABETIC AGENTS | GPR119, GCKR, GLP1R | KDM4E 853/4885FFAR1 220/4885PPARG 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.